Siga Technologies (NASDAQ:SIGA) and CASI Pharmaceuticals (NASDAQ:CASI) Financial Comparison
What Drove CASI Pharmaceuticals' 24% Rise After Hours?
CASI Pharmaceuticals Receives the Delisting Decision From the Nasdaq Hearings Panel
CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR)
CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia
CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements
CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing
CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual Meeting
CASI Pharmaceuticals Announces Changes in Board Governance
CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results
CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ
CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference
CASI Pharmaceuticals Announces Upcoming Presentation of Clinical Results for CID-103 at the 67th American Society of Hematology (ASH) Annual Meeting
CASI Pharmaceuticals Appoints James Huang to Board of Directors
CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference
CASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors
CASI Pharmaceuticals Announces Second Quarter 2025 Business and Financial Results
CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025
CASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft Antibody-Mediated Rejection (AMR)
CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program
CASI Pharmaceuticals Provides Business and Clinical Update
CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results
CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China
CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement
CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company
CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results
CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia
CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results
CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia
CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE
CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS
3 Promising Biotech Stocks You Can Pick Up for Less Than $10
CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS
CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP
CASI Pharmaceuticals (CASI) Up on Buyout Offer for China Business
CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company
CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He
CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP)
CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS
CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS
CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS
CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China
CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINA
CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATES
CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPA
CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES
Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals
CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339
Casi Pharmaceuticals to run clinical trial for multiple myeloma drug in China